Adalimumab biosimilar uptake among dermatologists in Medicare Part D through 2023: A retrospective analysis using the Prescribers - by Provider and Drug dataset.
- DOI
- 10.1016/j.jdin.2026.07.006
- Published
- 2026 Oct
- Container
- JAAD international
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jdin.2026.07.006,
title = {Adalimumab biosimilar uptake among dermatologists in Medicare Part D through 2023: A retrospective analysis using the Prescribers - by Provider and Drug dataset.},
author = {Schedler NC and Saqib M and Huang CA and Feldman SR},
year = {2026},
journal = {JAAD international},
doi = {10.1016/j.jdin.2026.07.006},
url = {https://doi.org/10.1016/j.jdin.2026.07.006}
}RIS
TY - JOUR TI - Adalimumab biosimilar uptake among dermatologists in Medicare Part D through 2023: A retrospective analysis using the Prescribers - by Provider and Drug dataset. AU - Schedler NC AU - Saqib M AU - Huang CA AU - Feldman SR PY - 2026 JO - JAAD international DO - 10.1016/j.jdin.2026.07.006 UR - https://doi.org/10.1016/j.jdin.2026.07.006 ER -
APA
NC, S., M, S., CA, H., & SR, F. (2026). Adalimumab biosimilar uptake among dermatologists in Medicare Part D through 2023: A retrospective analysis using the Prescribers - by Provider and Drug dataset.. JAAD international. https://doi.org/10.1016/j.jdin.2026.07.006
Source records
- pubmed · retrieved 2026-09-25T12:23:05.405Z
- europe-pmc · retrieved 2026-09-25T12:23:05.401Z
- doaj · retrieved 2026-09-25T12:23:05.408Z